H
Hans Lengsfeld
Researcher at Hoffmann-La Roche
Publications - 46
Citations - 1608
Hans Lengsfeld is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Lipase inhibitors & Lipase. The author has an hindex of 20, co-authored 46 publications receiving 1526 citations.
Papers
More filters
Journal ArticleDOI
Lipstatin, an inhibitor of pancreatic lipase, produced by streptomyces toxytricini
TL;DR: In mice triolein absorption was dose-dependently inhibited by lipstatin, whereas oleic acid was absorbed normally and other pancreatic enzymes, such as phospholipase A2 and trypsin, were not inhibited even at an inhibitor concentration of 200 microM.
Journal ArticleDOI
The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of test meals.
Frédéric Carrière,Christophe Renou,Véronique Lopez,Josiane De Caro,Francine Ferrato,Hans Lengsfeld,Alain De Caro,René Laugier,Robert Verger +8 more
TL;DR: The specific activities of HGL and HPL on meal TGs were much lower than those measured in vitro under optimized assay conditions (1300-8000), however, these low specific activities are enough for the Meal TGs to be completely lipolysed, given the amounts of H GL and H PL secreted during a meal.
Journal ArticleDOI
Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers
Frédéric Carrière,Christophe Renou,Stéphane Ransac,Véronique Lopez,Josiane De Caro,Francine Ferrato,Alain De Caro,Andre Fleury,Patricia Sanwald-Ducray,Hans Lengsfeld,Christoph Beglinger,Paul Hadvary,Robert Verger,René Laugier +13 more
TL;DR: The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans and found to be a powerful gastric lipase inhibitor, greatly reducing gastriclipolysis of solid and liquid meals.
Journal ArticleDOI
Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.
Olivier Morand,Johannes Aebi,Henrietta Dehmlow,Yu-Hua Ji,N Gains,Hans Lengsfeld,Jacques Himber +6 more
TL;DR: Findings clearly differentiate the OSC inhibitor Ro 48-8.071 from simvastatin, and support the view that OSC is a distinct key component in the regulation of the cholesterol synthesis pathway.
Journal ArticleDOI
Hydrolysis of dietary fat by pancreatic lipase stimulates cholecystokinin release
Pius Hildebrand,Christophe Petrig,Beat Burckhardt,Silvia Ketterer,Hans Lengsfeld,Andre Fleury,Paul Hadvary,Christoph Beglinger +7 more
TL;DR: These findings show that tetrahydrolipstatin prevents triglyceride hydrolysis and that plasma cholecystokinin release, gallbladder emptying, and pancreatic enzyme secretion require adequate triglyceride digestion.